Article
Current and future targeted therapies for non-small-cell lung cancers with aberrant EGF receptors.
Future oncology (London, England) - 1 Jan 2015
Kanthala Shanthi, Pallerla Sandeep, Jois Seetharama
Abstract excerpt
Expression of the EGF receptors (EGFRs) is abnormally high in many types of cancer, including 25% of lung cancers. Successful treatments target mutations in the EGFR tyrosine kinase domain with EGFR tyrosine kinase inhibitors (TKIs). However, almost all patients develop resistance to this treatment, and acquired resistance to first-generation TKI has prompted the clinical development of a second generation of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.